RBC Bioscience

RBC Bioscience Operating Cash Flow

The Operating Cash Flow of RBC Bioscience (6848.TWO) as of Oct 23, 2026 is 55.93 M TWD. In the previous year, Operating Cash Flow was 13.21 M TWD — a change of 323.45% (higher).

Operating Cash Flow

55.93 MTWD

YoY

323.45%

Last updated:

Operating Cash Flow of RBC Bioscience is 2024 55.93 M TWD. Operating Cash Flow of RBC Bioscience was 2023 13.21 M TWD. It decreases by 323.45% higher compared to the previous year.

The RBC Bioscience Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
3.92 M TWD
Jan 1, 2019
40.16 M TWD
Jan 1, 2020
205.68 M TWD
Jan 1, 2021
-25.30 M TWD
Jan 1, 2022
6.60 M TWD
Jan 1, 2023
13.21 M TWD
Jan 1, 2024
55.93 M TWD
The RBC Bioscience Operating Cash Flow history
YEAROperating Cash FlowYoY
55.93 MTWD+323.45%
13.21 MTWD+100.03%
6.60 MTWD-126.10%
-25.30 MTWD-112.30%
205.68 MTWD+412.21%
40.16 MTWD+923.32%
3.92 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Operating Cash Flow of RBC Bioscience is 55.93 M TWD in 2024.

Operating Cash Flow of RBC Bioscience changed from 13.21 M TWD to 55.93 M TWD, representing a 323.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's RBC Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RBC Bioscience

All Key Metrics — RBC Bioscience